Ovid Therapeutics (OVID) Cash from Operations (2016 - 2026)

Ovid Therapeutics (OVID) has reported Cash from Operations for 11 consecutive years, with -$17.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 268.66% year-over-year to -$17.6 million; the trailing twelve-month figure through Jun 2026 stood at -$54.8 million (down 36.71% YoY), and the FY2025 full-year result was -$38.3 million, up 31.49% from the prior year.
• Cash from Operations fell to -$17.6 million in Q2 2026 per OVID's latest filing, from -$13.9 million in the prior quarter.
• Across five years, Cash from Operations topped out at -$4.8 million in Q2 2025 and bottomed at -$20.1 million in Q1 2022.
• Historically, Cash from Operations has averaged -$12.6 million across 5 years, with a median of -$12.4 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash from Operations jumped 66.51% in 2025, then tumbled 268.66% in 2026.
• Over 5 years, Cash from Operations stood at -$9.2 million in 2022, then slipped by 29.81% to -$11.9 million in 2023, then climbed by 15.98% to -$10.0 million in 2024, then retreated by 4.0% to -$10.4 million in 2025, then tumbled by 69.1% to -$17.6 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$17.6 million, -$13.9 million, and -$10.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.